UNSPSC 51152048: Tolperisone

This classification denotes a muscle relaxant with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5EOM0LD8E, chemically known as 2,4-dimethyl-3-piperidinopropiophenone but generally known as tolperisone, which bears US NIH Compound Identifier 5511. European Medicines Agency schedules Tolperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11173MIG.

UNSPSC 51152048 Tolperisone is a Commodity code nominally identifying a specific muscle-relaxant pharmaceutical, but the recent state and local opportunities tagged under it show little alignment with that narrow scope. Seminole County, Florida posted an IFB in June 2026 for naloxone and drug deactivation systems—opioid-emergency and harm-reduction products entirely unrelated to tolperisone—and the Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription-fulfillment models for its broader pharmacy benefit program. The code appears to capture state and local pharmaceutical procurement at a commodity level, but the mismatch between the nominal chemical entity and the actual solicitations suggests inconsistent or potentially erroneous code assignment in the issuing bodies' systems. State and local health departments and health authorities are the primary buyers, focused on acquiring specific pharmaceuticals and managing pharmacy benefit logistics rather than any uniform product category.

Geographic activity centers on Florida and Texas based on recent postings. The Seminole County IFB (No. IFB60459723LAS, due July 26, 2026) calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term with optional one-year renewal. The Texas HHS RFI (No. HHS0017013, closed April 3, 2026) is exploratory and does not commit to contract values or timelines; it seeks vendor capability data on direct-to-manufacturer prescription models before formal RFP issuance. Neither solicitation specifies set-aside designations. The code shows sparse and scattered recent activity; business development professionals should verify code accuracy with the issuing body before committing significant pursuit effort, as the nominal scope (tolperisone) does not match observable procurement demand.